Liisa Bayko
Stock Analyst at Evercore ISI Group
(2.89)
# 1,407
Out of 4,829 analysts
81
Total ratings
42.86%
Success rate
52.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $37.59 | +163.37% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $21.54 | +108.91% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $10.34 | +16.05% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.54 | +224.68% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.19 | +268.42% | 2 | Dec 11, 2024 | |
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $3.02 | +65.84% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $26.84 | +30.40% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $300.76 | +19.70% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $270.19 | -3.77% | 1 | Jun 25, 2024 | |
| ANTX AN2 Therapeutics | Maintains: In-Line | $7 → $2 | $1.20 | +67.36% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $8.09 | +307.91% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $41.53 | -8.50% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $438 | $439.37 | -0.31% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $36.09 | +121.67% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $4.37 | +311.90% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $6.01 | +315.97% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $5.56 | +1,016.11% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.35 | +554.82% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $22.51 | +6.62% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $8.83 | +239.94% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.35 | +198.51% | 1 | Feb 5, 2020 |
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $37.59
Upside: +163.37%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $21.54
Upside: +108.91%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $10.34
Upside: +16.05%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.54
Upside: +224.68%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.19
Upside: +268.42%
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $3.02
Upside: +65.84%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $26.84
Upside: +30.40%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $300.76
Upside: +19.70%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $270.19
Upside: -3.77%
AN2 Therapeutics
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.20
Upside: +67.36%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $8.09
Upside: +307.91%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $41.53
Upside: -8.50%
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $439.37
Upside: -0.31%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $36.09
Upside: +121.67%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $4.37
Upside: +311.90%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $6.01
Upside: +315.97%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $5.56
Upside: +1,016.11%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.35
Upside: +554.82%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $22.51
Upside: +6.62%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $8.83
Upside: +239.94%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.35
Upside: +198.51%